CN101152154A - Hydrochloric acid dronedarone medicinal compositions for oral use and method for preparing the same - Google Patents
Hydrochloric acid dronedarone medicinal compositions for oral use and method for preparing the same Download PDFInfo
- Publication number
- CN101152154A CN101152154A CNA2006101134795A CN200610113479A CN101152154A CN 101152154 A CN101152154 A CN 101152154A CN A2006101134795 A CNA2006101134795 A CN A2006101134795A CN 200610113479 A CN200610113479 A CN 200610113479A CN 101152154 A CN101152154 A CN 101152154A
- Authority
- CN
- China
- Prior art keywords
- hydrochloric acid
- pharmaceutical composition
- dronedarone
- surfactant
- acid dronedarone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a solid drug combination, consisting of micronized hydrochlorid Dronedarone, surfactant and hydrophilic polymer which is used as cosolvent. The invention is mainly used to cure arrhythmia.
Description
Technical field
The present invention relates to a kind of novel solid composite medicament, especially contain the dronedarone or the pharmaceutical composition of acceptable salt pharmaceutically.
Background technology
Dronedarone (Dronedarone) chemistry 2-normal-butyl-3-[4-(3-di-n-butyl-amino propoxyl group) benzoyl by name]-5-methyl sulfanilamide benzofuran, molecular formula is C
31H
44N
2O
5S, molecular weight are 556.765.
The hydrochloric acid dronedarone is the treatment antiarrhythmic medicament by Sai Nuofei-up-to-date exploitation of first De Nabao company (Sanofi-Synthelabo).This product is not for containing the benzofuran analog derivative of iodine, and structure and feature and amiodarone are similar, but dronedarone does not contain iodine, lipotropy is lower, has therefore promptly kept the curative effect of amiodarone, and does not have the outer untoward reaction of the heart of amiodarone, and the half-life is 1～2 day, is more convenient for adjusting drug dose.
Hydrochloric acid dronedarone dissolubility in water-bearing media is very low, specifically its dissolubility at room temperature presents the pH dependency, in the scope of pH value 3 to 5, maxima solubility is arranged, be 1-2mg/ml approximately, about 6 to the 7 times dissolubility of pH become very low because its dissolubility under pH=7 is to have only 10 μ g/ml.
Just because of the dissolving characteristics of hydrochloric acid dronedarone, cause the bioavailability of its gastrointestinal administration low, because the process from the stomach to the intestinal is a process that pH raises gradually, the dissolubility that this means the hydrochloric acid dronedarone reduces gradually, this just cause the hydrochloric acid dronedarone can't be from solid preparation under the higher pH environment of intestinal stripping or dissolution very low.For improving the bioavailability of hydrochloric acid dronedarone, must find and to improve hydrochloric acid dronedarone dissolution approach.
US20040044070 discloses the injection of hydrochloric acid dronedarone.This invention has added beta-cyclodextrin derivative in buffer system (the pH value scope is 3-5), thereby has improved the dissolubility of effective ingredient.But the method for the dissolubility of this raising hydrochloric acid dronedarone, complicate fabrication process, and also stability may be relatively poor.
WO9858643 discloses a kind of solid composite medicament that contains benzofuran derivatives, it finds poloxamer class nonionic surfactant and dronedarone or its hydrochlorate, this active component is kept among the pH neutral 6-7 and can not separate out precipitation, improve the bioavailability of hydrochloric acid dronedarone.
Summary of the invention
The applicant is surprisingly found out that: micronized effective ingredient is scattered in makes suspension in the aqueous solution that comprises surfactant and hydrophilic polymer; be sprayed to then and prepare new pharmaceutical composition on the inert water-solubility carrier, this new method can successfully solve the dissolution problem of hydrochloric acid dronedarone.
The invention provides a kind of pharmaceutical composition, wherein contain micronized dronedarone or its pharmaceutically acceptable salt, surfactant and as the hydrophilic polymer of cosolvent.
The present invention also provides the method for preparing this kind pharmaceutical composition, and this method comprises following several steps:
(1) the hydrochloric acid dronedarone is pulverized with fluidized bed airflow, obtained the micronize hydrochloric acid dronedarone that mean diameter is less than or equal to 15nm;
(2) surfactant and hydrophilic polymer are dissolved in the water fully, the more micronized hydrochloric acid dronedarone of (1) gained are suspended wherein, obtain suspension;
(3) inertia water solublity holder is suspended in the fluidized bed pelletizer, the suspension of (2) gained is sprayed to carries out pelletize in the excipient, obtain granule;
(4) with (3) step gained granule, add other excipient, further be prepared into capsule or tablet.
The present invention also provides in hydrophilic polymer and surfactant, and average particle size is less than or equal to the suspension of the micronize form hydrochloric acid dronedarone of 15 μ m.
The dronedarone that the present invention relates to as active component is to be in the form that pharmaceutically can accept salt, preferably its hydrochlorate.
The micronize hydrochloric acid dronedarone that the present invention relates to can obtain by the fluidized bed airflow crushing technology, regulates grading wheel to 40 hertz, mean diameter be the hydrochloric acid dronedarone of 100nm-15 μ m.The related parameter that has that fluidized bed airflow is pulverized is 40 hertz for the grading wheel frequency; Cleaning pressure 0.6Mpa; Sealing load is 0.08Mpa; 0.8Mpa is pressed in the gas air inlet; The catcher back-flushing valve is at 0.6Mpa; Screw feeder is 150 rev/mins.
The particulate mean diameter of micronize hydrochloric acid dronedarone that the present invention uses is less than or equal to 15 μ m.
For general insoluble drugs, the more little dissolubility of particle diameter is big more.The present invention can cause the dissolution of the compositions for preparing with same steps as to can not get tangible improvement when finding that relatively mean diameter when hydrochloric acid dronedarone microgranule is greater than 15 μ m.But too small particle diameter must increase the power consumption of crushing process, and this industrialization to product is disadvantageous.
The particulate mean diameter of preferred micronized hydrochloric acid dronedarone is for being less than or equal to 8 μ m.
The content of micronize hydrochloric acid dronedarone is 10%-40% (weight), preferred 15%-30%.
The hydrophilic polymer that uses among the present invention is meant any high molecular weight material, this material has high affinity to glassware for drinking water and can be dissolved in wherein, the example of such polymer such as polyvinylpyrrolidone, polyvinyl alcohol, hypromellose, hydroxypropyl cellulose, hydroxy methocel and gelatin etc., mixture of polymers also is suitable for.
Preferred hydrophilic polymer is a polyvinylpyrrolidone.
Hydrophilic polymer accounts for the 2-10% of composition weight, is preferably 3-7%.
Surfactant of the present invention uses with common meaning, and any surfactant all is fit to, and is selected from the surfactant that at room temperature is solid-state or liquid, for example sodium lauryl sulfate, Tweens and spans, preferably sodium lauryl sulfate.
The 1-10% of surfactant comprise composition weight is preferably 3-7% weight.
The inertia water solublity holder of Shi Yonging is meant any excipients in the present invention, generally be hydrophilic, pharmaceutically inert, crystallization or unbodied, particle form, under employed operating condition, do not produce chemical reaction, and be soluble in water-bearing media.The example of such excipient is the derivant of sugar, as lactose, sucrose, maltodextrin etc.Mixture also is suitable for.
Can also include any excipient that is generally used for medicine and chemical field according to compositions of the present invention, this excipient is compatible with effective ingredient, as binding agent, wetting agent, disintegrating agent, correctives etc., for example can be used for excipient of the present invention can enumerate: microcrystalline Cellulose, pregelatinized Starch, magnesium stearate, polyvinylpolypyrrolidone, cross-linked carboxymethyl cellulose sodium, Pulvis Talci, micropowder silica gel etc.
Method of the present invention comprises the principle of using the fluidized bed prilling technology, but with specific parent material, improves dissolution and bioavailability to reach.Specifically, the present invention has used the suspension of the micronize effective ingredient in the solution of hydrophilic polymer and surfactant.
The fluidized bed prilling technology is widely used in pharmaceutical industries and prepares capsule or tablet; according to prior art; common mixture (effective ingredient+excipient) with powder or powder is placed on the fluid bed inner suspension in the comminutor, and the solution spray of binding agent and surfactant is gone up to form granule to this bed.The fluidized bed prilling technology is known those skilled in the art.
The suspension that the present invention includes micronize effective ingredient, surfactant and hydrophilic polymer sparges on the inert carrier; after the pelletize; the shot-like particle that forms comprises, for example, isolating lactose crystal, sticking pay the effective ingredient of plane of crystal and polyvinylpyrrolidone granule.
The shot-like particle that obtains directly fill capsule or compression is tablet, also can add other excipient and be prepared into capsule or be compressed into tablet.
Important initial substance is the suspension of effective ingredient, and this suspension prepares in the solution that comprises hydrophilic polymer and surfactant by micronized effective ingredient is suspended in.Hydrophilic polymer and surfactant under agitation are dissolved in the solvent, add micronized effective ingredient then, obtain the suspension of homogeneous with refiner homogenate.
The concentration of effective ingredient is 1-40% (weight) in the suspension, preferred 10-25%.
The concentration of hydrophilic polymer is 2-20% (weight) in the suspension, preferred 5-10%.
Surfactant concentrations is 0.5-10% (weight) in the suspension, preferred 2-6%.
The present invention will disperse the suspension of micronized effective ingredient, be sprayed to then to prepare new pharmaceutical composition on the inert water-solubility carrier, solve the dissolution problem of hydrochloric acid dronedarone, obtain satisfied effect.
The specific embodiment
The present invention is further elaborated by following examples, but whether will limit the invention by any way with it.
Embodiment 1:
| Composition | Percentage ratio % |
| The hydrochloric acid dronedarone | 20 |
| Sodium lauryl sulfate | 4 |
| Polyvinylpyrrolidone k30 | 4 |
| Lactose | 50 |
| Microcrystalline Cellulose PH101 | 21.5 |
| Magnesium stearate | 0.5 |
(1) the hydrochloric acid dronedarone is pulverized with fluidized bed airflow, obtained the micronize hydrochloric acid dronedarone of mean diameter less than 15nm;
(2) sodium lauryl sulfate and polyvinylpyrrolidone k30 are dissolved in the water fully, the micronize hydrochloric acid dronedarone with (1) gained suspends wherein again, obtains suspension;
(3) lactose is suspended in the fluidized bed pelletizer, the suspension of (2) gained is sprayed to carries out pelletize in the lactose, obtain granule;
(4) with (3) step gained granule, add into plain PH101 of microcrystalline cellulose and magnesium stearate, further be compressed into tablet.
Embodiment 2:
| Composition | Percentage ratio % |
| The hydrochloric acid dronedarone | 20 |
| Sodium lauryl sulfate | 4 |
| Polyvinylpyrrolidone k30 | 4 |
| Lactose | 50 |
| Microcrystalline Cellulose PH101 | 21.5 |
| Magnesium stearate | 0.5 |
(1) the hydrochloric acid dronedarone is pulverized with fluidized bed airflow, obtain mean diameter greater than 15 μ m the micronize hydrochloric acid dronedarone less than 50 μ m;
(2) sodium lauryl sulfate and polyvinylpyrrolidone k30 are dissolved in the water fully, the micronize hydrochloric acid dronedarone with (1) gained suspends wherein again, obtains suspension;
(3) lactose is suspended in the fluidized bed pelletizer, the suspension of (2) gained is sprayed to carries out pelletize in the lactose, obtain granule;
(4) with (3) step gained granule, add into plain PH101 of microcrystalline cellulose and magnesium stearate, further be compressed into tablet.
Embodiment 3:
| Composition | Percentage ratio % |
| The hydrochloric acid dronedarone | 20 |
| Polyvinylpyrrolidone k30 | 5 |
| Lactose | 50 |
| Microcrystalline Cellulose PH101 | 24.5 |
| Magnesium stearate | 0.5 |
(1) the hydrochloric acid dronedarone is pulverized with fluidized bed airflow, obtained the micronize hydrochloric acid dronedarone of mean diameter less than 15nm;
(2) polyvinylpyrrolidone k30 is dissolved in the water fully, the micronize hydrochloric acid dronedarone with (1) gained suspends wherein again, obtains suspension;
(3) lactose is suspended in the fluidized bed pelletizer, the suspension of (2) gained is sprayed to carries out pelletize in the lactose, obtain granule;
(4) with (3) step gained granule, add into plain PH101 of microcrystalline cellulose and magnesium stearate, further be compressed into tablet.
Embodiment 4:
| Composition | Percentage ratio % |
| The hydrochloric acid dronedarone | 20 |
| Sodium lauryl sulfate | 4 |
| Polyvinylpyrrolidone k30 | 4 |
| Lactose | 50 |
| Microcrystalline Cellulose PH101 | 21.5 |
| Magnesium stearate | 0.5 |
(1) the hydrochloric acid dronedarone is pulverized with fluidized bed airflow, obtained the micronize hydrochloric acid dronedarone of mean diameter less than 15 μ m;
(2) micronize hydrochloric acid dronedarone, sodium lauryl sulfate, polyvinylpyrrolidone k30, lactose and the microcrystalline Cellulose PH101 mix homogeneously that (1) step is obtained is wetting agent with water, granulate, and drying, granulate adds magnesium stearate, tabletting.
Embodiment 5: dissolution determination
With reference to Chinese Pharmacopoeia version appendix in 2005 XC, adopt the oar method, temperature is 37 ℃+0.5 ℃, the phosphate buffer 900ml of pH6.7 is a medium, in sampling in 5,10,20,30,45,60 minutes, and, calculate accumulation stripping percentage rate with determined by ultraviolet spectrophotometry A value.
| Time (min) | Accumulation stripping percentage rate (%) | |||||||
| Embodiment 1 | SD | Embodiment 2 | SD | Embodiment 3 | SD | Embodiment 4 | SD | |
| 5 10 20 30 45 60 | 10.8 36.5 53.4 65.5 85.0 95.2 | 1.04 0.36 0.84 0.75 0.96 0.89 | 5.36 13.5 20.3 31.8 34.6 34.2 | 0.94 0.72 1.24 0.76 0.46 0.77 | 7.83 25.47 40.15 58.31 70.14 78.99 | 0.47 0.89 0.79 0.53 1.26 1.42 | 4.37 13.5 15.3 15.8 15.6 16.2 | 0.42 0.49 1.02 0.73 0.91 1.04 |
From above dissolution data as can be seen; micronize hydrochloric acid dronedarone is scattered in the aqueous solution that comprises surfactant and hydrophilic polymer makes suspension in doing; be sprayed to then and prepare new pharmaceutical composition on the inert water-solubility carrier; significantly improve the dissolution of hydrochloric acid dronedarone, obtained satisfied effect.
Claims (9)
1. pharmaceutical composition is characterized in that containing micronized dronedarone or its pharmaceutically acceptable salt, surfactant and as the hydrophilic polymer of cosolvent.
2. pharmaceutical composition as claimed in claim 1 is characterized in that dronedarone can exist with hydrochlorate, acetate, maleate, citrate, tartrate form, preferably its hydrochlorate.
3. as the pharmaceutical composition of claim 1-2, the amount with respect to described pharmaceutical composition hydrochloric acid dronedarone of it is characterized in that is in 10-45% (weight), preferred 15-30%.
4. pharmaceutical composition as claimed in claim 1 is characterized in that described hydrophilic polymer is optional from polyvinylpyrrolidone, polyvinyl alcohol, hypromellose, hydroxypropyl cellulose, hydroxy methocel and gelatin or its mixture, preferably polyethylene ketopyrrolidine.
5. pharmaceutical composition as claimed in claim 4 is characterized in that hydrophilic polymer accounts for the 2-10% of composition weight, is preferably 3-7%.
6. as the pharmaceutical composition of right 1, it is characterized in that surfactant is a sodium lauryl sulfate.
7. pharmaceutical composition as claimed in claim 6 is characterized in that the 1-10% of surfactant comprise composition weight being preferably 3-7% weight.
8. as each pharmaceutical composition of claim, it is characterized in that the particulate mean diameter of micronize hydrochloric acid dronedarone is less than or equal to 15 μ m, preferably be less than or equal to 8 μ m.
9. as the preparation method of each described solid composite medicament of claim 1-8, comprise the following steps:
(1) the hydrochloric acid dronedarone is pulverized with fluidized bed airflow, obtained the microgranule of mean diameter less than 15 μ m;
(2) surfactant and hydrophilic polymer are dissolved in the water fully, the more micronized hydrochloric acid dronedarone of (1) gained are suspended wherein, obtain suspension;
(3) inertia water solublity holder is suspended in the fluidized bed pelletizer, the suspension of (2) gained is sprayed to carries out pelletize in the inertia water solublity holder, obtain granule;
(4) with (3) step gained granule, add other excipient, further be prepared into capsule or tablet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006101134795A CN100560067C (en) | 2006-09-29 | 2006-09-29 | Hydrochloric acid dronedarone medicinal compositions for oral use and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006101134795A CN100560067C (en) | 2006-09-29 | 2006-09-29 | Hydrochloric acid dronedarone medicinal compositions for oral use and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101152154A true CN101152154A (en) | 2008-04-02 |
| CN100560067C CN100560067C (en) | 2009-11-18 |
Family
ID=39254176
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006101134795A Expired - Fee Related CN100560067C (en) | 2006-09-29 | 2006-09-29 | Hydrochloric acid dronedarone medicinal compositions for oral use and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100560067C (en) |
Cited By (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2388256A1 (en) | 2007-10-02 | 2011-11-23 | Cambrex Karlskoga AB | Process for preparing benzofurans |
| WO2012013088A1 (en) * | 2010-07-30 | 2012-02-02 | 江苏恒瑞医药股份有限公司 | Dronedarone solid dispersion and preparation method thereof |
| CN102349889A (en) * | 2011-11-01 | 2012-02-15 | 江苏先声药物研究有限公司 | Composition containing dronedarone |
| WO2011135581A3 (en) * | 2010-04-28 | 2012-04-12 | Cadila Healthcare Limited | Pharmaceutical compositions of dronedarone |
| WO2011135582A3 (en) * | 2010-04-28 | 2012-04-26 | Cadila Healthcare Limited | Pharmaceutical compositions of dronedarone |
| CN102470121A (en) * | 2010-03-19 | 2012-05-23 | 江苏恒瑞医药股份有限公司 | Pharmaceutical compositions comprising dronedarone |
| WO2012085284A2 (en) * | 2010-12-24 | 2012-06-28 | Krka, D.D., Novo Mesto | High drug load pharmaceutical formulations comprising dronedarone and its pharmaceutically acceptable salts |
| CN102614139A (en) * | 2011-01-28 | 2012-08-01 | 杭州容立医药科技有限公司 | Solid pharmaceutical composition containing benzofuran derivative |
| CN102078307B (en) * | 2009-12-01 | 2012-11-07 | 天津市汉康医药生物技术有限公司 | Medicine composition of dronedarone hydrochloride solid dispersion and preparation method thereof |
| CN102908305A (en) * | 2011-08-05 | 2013-02-06 | 北京本草天源药物研究院 | Dronedarone hydrochloride-containing oral solid medicinal composition and preparation method thereof |
| WO2013024411A1 (en) * | 2011-08-12 | 2013-02-21 | Lupin Limited | Co-milled formulation of dronedarone |
| US8410167B2 (en) | 2008-04-17 | 2013-04-02 | Sanofi | Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality |
| CN103054820A (en) * | 2012-08-22 | 2013-04-24 | 石药集团中奇制药技术（石家庄）有限公司 | Dronedarone hydrochloride pharmaceutical composition and preparation method thereof |
| CN103328983A (en) * | 2010-12-10 | 2013-09-25 | 赛诺菲 | Use of dronedarone for the preparation of a drug for use in the management of the risk of liver injury |
| US8602215B2 (en) | 2010-06-30 | 2013-12-10 | Sanofi | Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation |
| CN104721178A (en) * | 2015-03-25 | 2015-06-24 | 河北仁合益康药业有限公司 | Composition for dronedarone hydrochloride tablet and preparation method thereof |
| CN105106152A (en) * | 2015-09-16 | 2015-12-02 | 迪沙药业集团有限公司 | Dronedarone hydrochloride composition |
| CN106265581A (en) * | 2016-09-30 | 2017-01-04 | 上海信谊万象药业股份有限公司 | A kind of tranexamic acid sheet and preparation method thereof |
| CN107049981A (en) * | 2017-04-11 | 2017-08-18 | 深圳市泛谷药业股份有限公司 | A kind of quick-release Amisulpride pharmaceutical composition and preparation method thereof |
| CN107184561A (en) * | 2017-06-01 | 2017-09-22 | 四川制药制剂有限公司 | The production technology of dronedarone hydrochloride piece |
| CN108042501A (en) * | 2017-12-28 | 2018-05-18 | 广东伊茗药业有限公司 | A kind of Dronedarone hydrochloride tablet without surfactant |
| CN108042489A (en) * | 2017-12-19 | 2018-05-18 | 佛山市弘泰药物研发有限公司 | A kind of dronedarone hydrochloride self-micro emulsion formulation and preparation method thereof |
| CN112618535A (en) * | 2020-12-30 | 2021-04-09 | 中山大学附属第六医院 | Application of dronedarone in preparation of medicine for preventing and treating colitis |
-
2006
- 2006-09-29 CN CNB2006101134795A patent/CN100560067C/en not_active Expired - Fee Related
Cited By (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2388256A1 (en) | 2007-10-02 | 2011-11-23 | Cambrex Karlskoga AB | Process for preparing benzofurans |
| US8410167B2 (en) | 2008-04-17 | 2013-04-02 | Sanofi | Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality |
| US9107900B2 (en) | 2008-04-17 | 2015-08-18 | Sanofi | Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of morality |
| CN102078307B (en) * | 2009-12-01 | 2012-11-07 | 天津市汉康医药生物技术有限公司 | Medicine composition of dronedarone hydrochloride solid dispersion and preparation method thereof |
| CN102470121A (en) * | 2010-03-19 | 2012-05-23 | 江苏恒瑞医药股份有限公司 | Pharmaceutical compositions comprising dronedarone |
| WO2011135581A3 (en) * | 2010-04-28 | 2012-04-12 | Cadila Healthcare Limited | Pharmaceutical compositions of dronedarone |
| WO2011135582A3 (en) * | 2010-04-28 | 2012-04-26 | Cadila Healthcare Limited | Pharmaceutical compositions of dronedarone |
| US8602215B2 (en) | 2010-06-30 | 2013-12-10 | Sanofi | Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation |
| CN102481281A (en) * | 2010-07-30 | 2012-05-30 | 江苏恒瑞医药股份有限公司 | Dronedarone solid dispersion and preparation method thereof |
| US8921416B2 (en) | 2010-07-30 | 2014-12-30 | Jiangsu Hengrui Medicine Co., Ltd. | Dronedarone solid dispersion and preparation method thereof |
| WO2012013088A1 (en) * | 2010-07-30 | 2012-02-02 | 江苏恒瑞医药股份有限公司 | Dronedarone solid dispersion and preparation method thereof |
| CN103328983A (en) * | 2010-12-10 | 2013-09-25 | 赛诺菲 | Use of dronedarone for the preparation of a drug for use in the management of the risk of liver injury |
| WO2012085284A3 (en) * | 2010-12-24 | 2012-09-20 | Krka, D.D., Novo Mesto | High drug load pharmaceutical formulations comprising dronedarone and its pharmaceutically acceptable salts |
| WO2012085284A2 (en) * | 2010-12-24 | 2012-06-28 | Krka, D.D., Novo Mesto | High drug load pharmaceutical formulations comprising dronedarone and its pharmaceutically acceptable salts |
| CN102614139A (en) * | 2011-01-28 | 2012-08-01 | 杭州容立医药科技有限公司 | Solid pharmaceutical composition containing benzofuran derivative |
| CN102908305B (en) * | 2011-08-05 | 2016-06-22 | 北京本草天源药物研究院 | A kind of oral solid drug composition containing dronedarone hydrochloride and preparation method thereof |
| CN102908305A (en) * | 2011-08-05 | 2013-02-06 | 北京本草天源药物研究院 | Dronedarone hydrochloride-containing oral solid medicinal composition and preparation method thereof |
| WO2013024411A1 (en) * | 2011-08-12 | 2013-02-21 | Lupin Limited | Co-milled formulation of dronedarone |
| CN102349889B (en) * | 2011-11-01 | 2013-08-28 | 江苏先声药物研究有限公司 | Composition containing dronedarone |
| CN102349889A (en) * | 2011-11-01 | 2012-02-15 | 江苏先声药物研究有限公司 | Composition containing dronedarone |
| CN103054820A (en) * | 2012-08-22 | 2013-04-24 | 石药集团中奇制药技术（石家庄）有限公司 | Dronedarone hydrochloride pharmaceutical composition and preparation method thereof |
| CN103054820B (en) * | 2012-08-22 | 2016-07-13 | 石药集团中奇制药技术（石家庄）有限公司 | A kind of Dronedarone hydrochloride pharmaceutical composition and preparation method thereof |
| CN104721178A (en) * | 2015-03-25 | 2015-06-24 | 河北仁合益康药业有限公司 | Composition for dronedarone hydrochloride tablet and preparation method thereof |
| CN105106152A (en) * | 2015-09-16 | 2015-12-02 | 迪沙药业集团有限公司 | Dronedarone hydrochloride composition |
| CN105106152B (en) * | 2015-09-16 | 2019-09-13 | 迪沙药业集团有限公司 | A kind of dronedarone hydrochloride composition |
| CN106265581A (en) * | 2016-09-30 | 2017-01-04 | 上海信谊万象药业股份有限公司 | A kind of tranexamic acid sheet and preparation method thereof |
| CN107049981A (en) * | 2017-04-11 | 2017-08-18 | 深圳市泛谷药业股份有限公司 | A kind of quick-release Amisulpride pharmaceutical composition and preparation method thereof |
| CN107184561A (en) * | 2017-06-01 | 2017-09-22 | 四川制药制剂有限公司 | The production technology of dronedarone hydrochloride piece |
| CN108042489A (en) * | 2017-12-19 | 2018-05-18 | 佛山市弘泰药物研发有限公司 | A kind of dronedarone hydrochloride self-micro emulsion formulation and preparation method thereof |
| CN108042501A (en) * | 2017-12-28 | 2018-05-18 | 广东伊茗药业有限公司 | A kind of Dronedarone hydrochloride tablet without surfactant |
| CN112618535A (en) * | 2020-12-30 | 2021-04-09 | 中山大学附属第六医院 | Application of dronedarone in preparation of medicine for preventing and treating colitis |
| CN112618535B (en) * | 2020-12-30 | 2022-04-12 | 中山大学附属第六医院 | Application of dronedarone in preparation of medicine for preventing and treating colitis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100560067C (en) | 2009-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100560067C (en) | Hydrochloric acid dronedarone medicinal compositions for oral use and preparation method thereof | |
| WO2022012172A1 (en) | Oral sustained-release composition for insoluble drug, and preparation method thereof | |
| JP2008528456A (en) | Novel pharmaceutical composition comprising candesartan cilexetil as lipophilic crystalline substance | |
| CN102908305B (en) | A kind of oral solid drug composition containing dronedarone hydrochloride and preparation method thereof | |
| CN107397732A (en) | The method for improving Ezetimibe piece dissolution rate | |
| CN103239719A (en) | Metformin compound pharmaceutical composition and preparation method thereof | |
| CN104586795B (en) | A kind of canagliflozin piece and preparation method thereof | |
| CN102406622B (en) | Tolvaptan solid preparation | |
| CN103877051A (en) | Preparation method of ezetimibe tablet | |
| CN109793715B (en) | Apixaban oral solid preparation and preparation method thereof | |
| CN115624525A (en) | Tacrolimus sustained-release pharmaceutical composition and preparation method thereof | |
| CN112933061B (en) | Arbidol hydrochloride capsule and preparation method thereof | |
| CN104771375B (en) | A kind of Dronedarone hydrochloride tablet and preparation method thereof | |
| CN111249245A (en) | Vitamin B2Quick release tablet and preparation method thereof | |
| CN103315972B (en) | A kind of Moxifloxacin hydrochloride tablet and preparation method thereof | |
| JP6072705B2 (en) | Solid dispersion formulation | |
| CN109730969B (en) | Lactic acid levofloxacin dispersible tablet and preparation method thereof | |
| WO2002100407A1 (en) | Itraconazole granulations: pharmaceutical formulations for oral administration and method of preparing same | |
| CN113750067B (en) | Preparation process of levofloxacin tablets | |
| CN112972396A (en) | Febuxostat controlled-release composition and preparation method thereof | |
| CN112057427A (en) | Oral solid tablet containing Bruton's tyrosine kinase inhibitor and preparation method thereof | |
| CN113521022B (en) | Sustained-release tablet containing alexidine and preparation method thereof | |
| CN107041873B (en) | Preparation method of sofosbuvir coated tablet | |
| CN109925293B (en) | Eplerenone oral solid preparation and preparation method thereof | |
| CN109125278B (en) | Iloperidone medicinal oral preparation and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: BEIJING VENTUREPHARM BIOTECHNOLOGY CORP. Free format text: FORMER OWNER: DEZHONG WANQUAN PHARMACEUTICALS TECH. DEV. CO., LTD., BEIJING Effective date: 20140925 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100097 HAIDIAN, BEIJING TO: 102206 CHANGPING, BEIJING |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20140925 Address after: 102206 Beijing City, Changping District Zhongguancun Life Science Park Boda tower Patentee after: Beijing Wanquan Dezhong Medical Biological Technology Co., Ltd. Address before: 100097 Beijing city Haidian District Sijiqing Wanquan Zhuang 3 Building Patentee before: Dezhong Wanquan Pharmaceuticals Tech. Dev. Co., Ltd., Beijing |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20091118 Termination date: 20140929 |
|
| EXPY | Termination of patent right or utility model |